Biocon Performance
- Today's Low
- ₹422
- Today's High
- ₹433
- 52 Week Low
- ₹328
- 52 Week High
- ₹437
- Open Price₹433
- Previous Close₹431
- Volume3,777,650
- 50 DMA₹385.76
- 100 DMA₹380.37
- 200 DMA₹374.38
Biocon Chart
Investment Returns
- Over 1 Month + 20.18%
- Over 3 Month + 10.97%
- Over 6 Month + 8.42%
- Over 1 Year + 30.08%
Smart Investing Starts Here Start SIP with Biocon for Steady Growth!
Biocon Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 180.9
- PEG Ratio
- -2.9
- Market Cap Cr
- 69,740
- P/B Ratio
- 2.6
- Average True Range
- 11.69
- EPS
- 2.4
- Dividend Yield
- 0.1
- MACD Signal
- 13.95
- RSI
- 75.79
- MFI
- 91.64
Latest Stock News Updates
In the past 12 trading days, the market price of Biocon has appreciated by 20 per cent from a level of 349.65 on the BSE on April 24, 2026.
- Business Standard
- 1 week 4 days ago
Kiran Mazumdar-Shaw explained why she has chosen her niece, Claire, as her successor, outlining a five-year transition plan that will eventually see Claire take over as chairperson
- Business Standard
- 2 weeks 1 day ago
Biocon founder Kiran Mazumdar-Shaw outlines a five-year transition plan, naming niece Claire Mazumdar as successor to lead the company's next growth phase
- Business Standard
- 2 weeks 5 days ago
Biocon Financials
Biocon Technicals
EMA & SMA
- Bearish Moving Average 0
- Bullish Moving Average 16
- 20 Day
- ₹402.48
- 50 Day
- ₹385.76
- 100 Day
- ₹380.37
- 200 Day
- ₹374.38
Resistance and Support
- R3 446.50
- R2 439.85
- R1 435.05
- S1 423.60
- S2 416.95
- S3 412.15
Biocon Corporate Actions - Bonus, Splits, Dividends
| Date | Purpose | Remarks |
|---|---|---|
| 2026-05-07 | Audited Results & Final Dividend | |
| 2026-02-12 | Quarterly Results | |
| 2025-11-11 | Quarterly Results | |
| 2025-10-01 | Redemption (Part) of NCD | Inter alia, it is proposed to consider early redemption of unlisted, secured, rated, redeemable, Non-Convertible Debentures (NCDs) of face value of INR 1,00,000/- each. per share(10%)Final Dividend |
| 2025-08-07 | Quarterly Results |
Biocon F&O
About Biocon
Biocon limited is a biopharmaceutical company in India and it is Asia's largest biotechnology company. The company was founded by Kiran Mazumdar-Shaw in 1978 and is headquartered in Bengaluru, India. The company has more than 16,545 employees as on March 2023. It focuses on all phases of the product cycle from researching to development and then introducing them to the market. They mainly concentrate on the research and development of advanced therapies for the treatment of cancer, diabetes, and autoimmune disease. The company's medicines are helping the lives of patients in more than 120 countries by providing access to all their medicines and therapies.
Some of Biocon's important brands in India are INSUGEN (rh-insulin), BIOMAb EGFR (Nimotuzumab), CANMAb (Trastuzumab),KRABEVA (Bevacizumab), ALZUMAb(Itolizumab), BLISTO (Glimepiride + Metformin), BASALOG (Glargine) & so on.
View More- NSE Symbol
- BIOCON
- BSE Symbol
- 532523
- Managing Director & CEO
- Mr. Siddharth Mittal
- ISIN
- INE376G01013
Similar Stocks to Biocon
Popular Stocks
Biocon FAQs
Biocon share price is ₹430 As on 24 May, 2026 | 20:05
The Market Cap of Biocon is ₹69739.6 Cr As on 24 May, 2026 | 20:05
The P/E ratio of Biocon is 180.9 As on 24 May, 2026 | 20:05
The PB ratio of Biocon is 2.6 As on 24 May, 2026 | 20:05
Biocon has an operating revenue of Rs.7,290.70 Cr. on a trailing 12-month basis. An annual revenue growth of 14% is good, Pre-tax margin of 16% is great. However, analysts are of mixed views on the stock.
Biocon Ltd. has declared 17 dividends since July 1, 2004.
The stock price CAGR of Biocon Limited for 10 Years is 24%, 5 Years is 17%, 3 Years is 5%, 1 Year is -21%.
The debt-to-equity ratio of Biocon Limited is 39% which signals a healthy balance sheet.
The ROE of Biocon Limited is 9% which is fair but needs improvement.
Mr. Siddharth Mittal is the Managing Director and CEO of Biocon Limited.
According to the record analysis of moneyworks4me, Biocom limited is an average quality company.
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.